FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and pharmaceutics and concerns gram-positive pathogen growth inhibitors representing (+) and (-)-enantiomers of usnic acid derivatives containing a quaternised nitrogen atom. The inhibitors possess high biological activity.
EFFECT: invention provides effective action on mycobacteria and thereby increased clinical effectiveness in tuberculosis.
8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FURILIDENE FURANONE DERIVATIVES OF USNIC ACID AS NEW ANTITUBERCULOSIS AGENTS | 2013 |
|
RU2533707C1 |
| AMINOTHIAZOLE DERIVATIVES OF USNIC ACID AS NOVEL ANTI-TUBERCULOSIS AGENTS | 2012 |
|
RU2483722C1 |
| AGENT FOR INHIBITING HUMAN POLY(ADP-RIBOSE)POLYMERASE-1 ENZYME | 2012 |
|
RU2500675C1 |
| AGENT FOR INHIBITING HUMAN TYROSYL-DNA-PHOSPHODIESTERASE 1 ENZYME | 2015 |
|
RU2605329C1 |
| HYDRAZINE THIAZOLE DERIVATIVES OF USNIC ACID WITH INHIBITORY ACTION TOWARDS HUMAN TYROSYL-DNA-PHOSPHODIESTERASE 1 ENZYME | 2015 |
|
RU2612256C1 |
| 2-ACETYL-6-(2-(2-(4-BROMBENZYLIDENE)HYDRAZINYL)THIAZOL-4-YL)-3,7,9-TRIHYDROXY-8,9B-DIMETHYLDIOBENZO[B,D]FURAN-1(9BH)-OH, WITH INHIBITING ACTION ON HUMEN TYROSYL-DNA-PHOSPHODIESTERASE 1 | 2016 |
|
RU2627764C1 |
| INDANONE DERIVATIVE, ITS PHARMACEUTICALLY ACCEPTABLE SALT OR ENANTIOMER, METHOD FOR PRODUCING IT AND PHARMACEUTICAL COMPOSITION CONTAINING IT AND APPLICABLE FOR PREVENTING OR TREATING VIRAL DISEASE | 2012 |
|
RU2574591C2 |
| USNIC ACID DERIVATIVES AS ANTI-TUMOUR AGENTS | 2013 |
|
RU2536873C1 |
| 1,3-DIOXOINDENE DERIVATIVES, THEREOF PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF OBTAINING THEREOF AND PHARMACEUTICAL ANTIVIRAL COMPOSITION, CONTAINING IT AS ACTIVE INGREDIENT | 2012 |
|
RU2566761C2 |
| PHARMACEUTICAL COMPOSITION, INCLUDING TRICYCLIC SULFUR-CONTAINING 1,2-DIHYDROQUINOLINE DERIVATIVE FOR INHIBITION OF REPLICATION OF BETA CORONAVIRUSES, INCLUDING SARS-CoV-2, AND METHOD OF ITS USE | 2021 |
|
RU2814434C1 |
